Collegium Pharmaceutical Inc (COLL) Stock Analysis

Verdict: WATCH (do not buy)

ADHD portfolio growth (JORNAY PM, AZSTARYS) is offset by Nucynta generic pricing pressure and $857.8M debt, making re-rating reliant on debt paydown.

Investment score: 52/100

Analysis as of

Is Collegium Pharmaceutical Inc stock worth reviewing? The TradeMates thesis

TradeMates evaluates Collegium Pharmaceutical as a WATCH candidate. Although trading at an attractive 3.17x EV/EBITDA with strong free cash flow generation ($327.6M in 2025), $857.8M in total debt and revenue headwinds from Nucynta generic pricing keep short-term upside capped until execution on the AZSTARYS integration is proven.

7-factor investment score

Collegium Pharmaceutical Inc opportunities and risks

What speaks for COLL

What speaks against COLL

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
COLL15.5x1.0x3.2x60.0%5.9%42.5%
SGPn/a0.0xn/a0.0%0.0%-5.3%
ALMSn/a119.0xn/a88.2%-5933.5%-40.0%
ANROn/a0.0xn/a0.0%0.0%-7.8%
LXRXn/a16.4xn/a98.9%-147.4%-11.7%
Peer mediann/a8.2xn/a44.1%-73.7%-9.8%

Frequently asked questions about Collegium Pharmaceutical Inc (COLL)

Is COLL stock a good investment?

The TradeMates model rates Collegium Pharmaceutical Inc as WATCH (do not buy) with an investment score of 52/100. TradeMates evaluates Collegium Pharmaceutical as a WATCH candidate. Although trading at an attractive 3.17x EV/EBITDA with strong free cash flow generation ($327.6M in 2025), $857.8M in total debt and revenue headwinds from Nucynta generic pricing keep short-term upside capped until execution on the AZSTARYS integration is proven. This is algorithmic model output, not personal investment advice.

Is COLL stock a buy?

The TradeMates model verdict for COLL is WATCH (do not buy) with an investment score of 52/100. Treat this as a model signal to review, not a personal buy recommendation.